0.479
0.03 (7.14%)
| Penutupan Terdahulu | 0.447 |
| Buka | 0.450 |
| Jumlah Dagangan | 62,729,049 |
| Purata Dagangan (3B) | 29,066,625 |
| Modal Pasaran | 165,772,768 |
| Harga / Jualan (P/S) | 4.01 |
| Harga / Buku (P/B) | 2.01 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 15 May 2025 |
| Margin Operasi (TTM) | -20,952.04% |
| EPS Cair (TTM) | -1.23 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 22.79% |
| Nisbah Semasa (MRQ) | 2.12 |
| Aliran Tunai Operasi (OCF TTM) | -14.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -6.95 M |
| Pulangan Atas Aset (ROA TTM) | -76.74% |
| Pulangan Atas Ekuiti (ROE TTM) | -201.87% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menaik | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menaik | Bercampur | |
| Stok | Incannex Healthcare Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.88 |
|
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 26.14% |
| % Dimiliki oleh Institusi | 8.65% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Arete Wealth Advisors, Llc | 30 Sep 2025 | 1,178,588 |
| Abacus Wealth Partners, Llc | 30 Sep 2025 | 250,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 03 Dec 2025 | Pengumuman | Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA) |
| 20 Nov 2025 | Pengumuman | Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2026 |
| 30 Oct 2025 | Pengumuman | Incannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic Focus |
| 22 Oct 2025 | Pengumuman | Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |